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Antibacterial activityAbstract Biologically active compounds with heteroaromatic ring system of cefotaxime sodium
have been synthesized via aminomethylation reaction. The aminomethylation of cefotaxime sodium
with various biologically potent sulphonamides/secondary amines was carried out and then
characterized by elemental analysis and spectral studies – IR, 1H NMR, 13C NMR, Powder
X-ray diffraction and Scanning Electron Microscopy. The compounds were screened for their anti-
bacterial activity against various pathogenic bacteria at varying concentrations. The antibacterial
activity of cefotaxime sodium derivatives was compared with parent sulphonamides. The toxicity
of synthesized cefotaxime sodium derivatives was ascertained by LD50 test.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the introduction of the ﬁrst antibiotic (penicillin, 1942)
into medical practice, to date, there has been an ongoing
‘‘race’’ between scientists creating new drugs and pathogenic
bacteria. This speciﬁc ‘‘arms race’’ causes that thousands ofpotentially active chemicals are synthesized in laboratories
around the world every day.
Cefotaxime sodium drug belongs to the third generation of
cephalosporin. It has potent broad spectrum of activity against
important pathogens (Zhang et al., 2006) and (Raddatz et al.,
1995). It is considered as one of the ﬁrst choice antibiotics in
the therapy of spontaneous bacterial peritonitis in cirrhosis
(Gilbert and Kamath, 1995) and (Rimola et al., 1995). Cefotax-
ime is a semi-synthetic cephalosporin consisting of an acetyl
side-chain on aminothiazolyl ring and an alpha-syn-methoxy-
imino group (Bucourt et al., 1980). The molecular formula is
C16H16N5NaO7S2 and molecular weight is 477. Its IUPAC
name is sodium (6R, 7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-
(methoxyimino) acetamido]-3-acetyl-oxymethyl-3-cephem-4-
carboxylate.
In addition to this the sulphonamide is well-known antim-
icrobial agents (Joshi et al., 2004; Wilkinson et al., 2007;
Kamal et al., 2007; Joshi et al., 2012), anti-inﬂammatoryivatives.
2 S. Joshi et al.(Bashir et al., 2011), antiproliferative (Hu et al., 2007), Car-
bonic anhydrase inhibitors (Garaj et al., 2004; Lehtonen
et al., 2004; Puccetti et al., 2005; Zimmerman et al., 2004;
Gu¨zel et al., 2009) anti-tumour Crespo et al., 2010) and
radiosensitizing agents (Ghorab et al., 2010).
The aminomethylation incorporated with sulphonamides is
reported to be potent antibacterial agents and less toxic than
parent sulphonamide (Joshi et al., 2007, 2010). Keeping in
view the unique features of cefotaxime sodium and sulphona-
mide were condensed via aminomethylation reaction. A series
of cefotaxime sodium derivatives were synthesized with
different sulphonamides/secondary amines (Schemes 1 and
2). The synthesized compounds were characterized by elemen-
tal analysis and spectral studies – IR, 1H NMR, 13C NMR,
Powder XRD, SEM and screened for in vitro antibacterial
activity gram-positive and gram-negative bacteria at arbitrarily
chosen concentrations.
2. Experimental
All the melting points were determined in open capillary tubes
and were uncorrected. Thin layer chromatography was used
for monitoring the reaction and to check purity. IR spectra
(KBr) were recorded as potassium bromide pellets onScheme 1 Synthesis of cefotaxime sod
Please cite this article in press as: Joshi, S. et al., Synthesis, spectroscopic characteri
Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.031Schimadzu 820 IPC FTIR spectrometer and 1H NMR spectra
on Bruker DRX-300 FT NMR Spectrometer and chemical
shifts were expressed as (ppm) values against tetramethylsilane
(TMS) as internal reference. The XRD measurements were
carried out on Bruker D8 Advance X-ray diffractometer using
Cu Ka at a wavelength of 1.54 A˚. SEM studies were performed
with a Jeol JSM 5600 instrument having magniﬁcation range
·18 to ·300,000 and at an accelerating voltage of 0.5–30 kV.
The chemical reagents used in the synthesis were purchased
from E. Merck and Aldrich. All substituted sulphonamides
were obtained as pure samples from reputed pharmaceutical
establishment.
2.1. Chemistry
The reaction routes for synthesis of cefotaxime sodium deriv-
atives were described as shown in Schemes 1 and 2.
2.1.1. Synthesis of cefotaxime sodium methyl sulphonamide (3a–
3f) (Scheme 1)
To the ethanolic solution of 0.1 mol of cefotaxime sodium was
added to 0.1 mol of sulphonamide slowly with constant stir-
ring under rigorous ice cooling. The reaction mixture was
cooled well and 2.5 ml of formaldehyde solution (37% v/v)ium methyl sulphonamide (3a–3f).
zation and Antibacterial screening of some new cefotaxime sodium derivatives.
Scheme 2 Synthesis of cefotaxime sodium methyl amines (3g–3j).
Effects of some new cefotaxime sodium derivatives 3was added slowly with constant stirring. The reaction mixture
was then adjusted to the pH of 3.5 with hydrochloric acid. The
reaction mixture was kept in efﬁcient ice cooling for half an
hour to avoid losses of formaldehyde and then reﬂuxed on
water bath. The reﬂux time was dependent upon the sulphona-
mide chosen. After reﬂuxing, the reﬂuxed mixture was cooled
in refrigerator for 4 days, till crystallized product was
obtained, which was recrystallized with dry distilled ethanol
and DMF (1:1). Melting points were recorded and uncor-
rected. The purity of the compounds was ascertained by single
spot during TLC where mobile phase was chloroform/metha-
nol mixture (90:10) and stationary phase was silica gel-G
(chromatographic grade).2.1.2. Synthesis of cefotaxime sodium methyl amines (3g–3j)
(Scheme 2)
Secondary amines (0.01 mol) were added to an ethanolic solu-
tion (50 ml) of Cefotaxime sodium (0.01 mol) in a ﬂat-bottom
ﬂask. One half of 0.015 mol of formaldehyde solution (37%)
was added slowly with constant stirring. The reaction mixture
was stirred at 70–75 C on a magnetic stirrer for 5.5 and 8.5 h,
except for diethanolamine (3h), depending upon the secondary
amine taken. The remaining portion of formaldehyde solution
was added in two instalments at an interval of 1 h, where ﬁrst
instalment was added immediately and second was added after
one hour from start of experiment. The reaction mixture was
kept overnight in the refrigerator. Next day excess of solvent
was distilled off from the reaction mixture through vacuum
pump which is under reduced pressure. Next day it was
again kept for crystallization in the refrigerator. The productPlease cite this article in press as: Joshi, S. et al., Synthesis, spectroscopic characteri
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ethanol. Melting point was recorded and found uncorrected.
The compounds thus synthesized are presented in Schemes
1 and 2.
2.2. Spectral studies
2.2.1. IR and NMR studies
Compound 3a: cefotaxime sodium methyl sulpha methoxazole;
C27H27N8NaO10S3; yield 80%, m.p. 160–163 C. Anal. Calcd
C, 43.66; H, 3.66; N, 15.09 Found C, 43.62; H, 3.42; N,
15.03. IR (KBr) mmax in cm
1: 3442 ms NAH, 3398 mas NAH
in SO2NH, 2972 CAH Aliphatic, 2940 mas CAH in CH2,
1779 ms C‚O in beta lactam, 1657 ms C‚O in amide, 1622 ms
C‚O in COONa, 1586 ms C‚N, 1538 NAH bending, 1345
ms S‚O, 1130 CAH in plane bending vibration of 1:4 disubsti-
tuted benzene, 1033 ms NAO.
1H NMR (DMSO) d ppm: 3.73
(s, 3H, CH3ACOO), 2.94 (s, 2H, CH2ACOO), 3.57 and 3.41
(ABq, 2H, CH2 attached to thiazine ring), 5.05 (d, 1H, CH
attached to thiazine ring), 5.59 (dd, 1H, CH attached to azeti-
dine ring), 9.53 (d, 1H, NHAC‚0 of cefotaxime), 3.84 (s, 3H,
NOACH3), 6.74 (d, 1H, CH attached to thiazole ring), 7.84 (s,
1H, NHACH2ANH), 4.83 (d, 2H, NACH2AN0), 6.34 (s, 1H,
CH2ANH0), 9.03 (s, 1H, SO2NH), 6.6–7.2 (m, ring proton of
sulphonamide). 13C NMR (DMSO), d ppm: 12.58 (CH3
attached to oxazole), 25.78 (CH2 attached to thiazine), 37.11
(CH2ACOO), 52.06 (CH3ACOO), 52.32 (ANACH2ANA),
57.72 (CH attached to thiazine), 59.64 (CH attached to azeti-
dine), 62.98 (NAOACH3), 114.74 (CH attached to thiazole),
168.22 (COOANa), 171.67(COO), 113.47, 128.88, 149.50,
130.24.zation and Antibacterial screening of some new cefotaxime sodium derivatives.
4 S. Joshi et al.Compound 3b: cefotaxime sodium methyl Sulphacetamide;
C25H26N7NaO10S3; yield 72%, m.p. 105–107 C. Anal. Calcd.
C, 42.67; H, 3.72; N, 13.93; Found C, 42.61; H, 3.66; N, 13.90.
IR (KBr) mmax in cm
1: 3440 ms NAH, 3392 mas NAH in SO2-
NH, 2970 ms CAH Aliphatic, 2946 mas CAH in CH2, 1774 ms
C‚O in beta lactam, 1655 ms C‚O in amide, 1620 ms C‚O
in COONa, 1582 ms C‚N, 1530 NAH bending, 1342 ms
S‚O, 1133 CAH in plane bending vibration of 1:4 disubsti-
tuted benzene, 1035 ms NAO.
1H NMR (DMSO) d ppm:
3.74 (s, 3H, CH3ACOO), 2.96 (s, 2H, CH2ACOO), 3.55 and
3.42 (ABq, 2H, CH2 attached to thiazine ring), 5.04 (d, 1H,
CH attached to thiazine ring), 5.57 (dd, 1H, CH attached to
azetidine ring) 9.54 (d, 1H, NHAC‚0 of cefotaxime), 3.82
(s, 3H, NOACH3), 6.71 (d, 1H, CH attached to thiazole ring),
7.80 (s, 1H, NHACH2ANH0), 4.82 (d, 2H, NACH2AN0), 6.30
(s, 1H, CH2ANH0), 9.06 (s, 1H, SO2NH), 6.6–7.07 (m, ring
proton of sulphonamide). 13C NMR (DMSO), d ppm: 22.43
(COACH3) 25.70 (CH2 attached to thiazine), 37.16 (CH2
ACOO), 52.06 (CH3ACOO), 52.33 (ANACH2ANA), 57.77
(CH attached to thiazine), 59.67 (CH attached to azetidine),
62.97 (NAOACH3), 114.71 (CH attached to thiazole), 162.90
(COANH), 168.06 (COACH3), 168.20 (COOANa), 171.66
(COO), 113.47, 128.88, 149.50, 130.28.
Compound 3c: cefotaxime sodium methyl Sulphacetamide
sodium; C25H25N7Na2O10S3; yield 84%, m.p. 180–181 C,
Anal. Calcd. C, 41.38; H, 3.47; N, 13.51; Found C, 41.33; H,
3.45; N, 13.43. IR (KBr) mmax in cm
1: 2973 ms CAH Aliphatic,
2938 mas CAH in CH2, 1775 ms C‚O in beta lactam, 1659 ms
C‚O in amide, 1618 ms C‚O in COONa, 1585 ms C‚N,
1533 NAH bending, 1338 ms S‚O, 1130 CAH in plane bend-
ing vibration of 1:4 disubstituted benzene, 1038 ms NAO.
1H
NMR (DMSO) d ppm: 3.75 (s, 3H, CH3ACOO), 2.90 (s,
2H, CH2ACOO), 3.57 and 3.41 (ABq, 2H, CH2 attached to
thiazine ring), 5.03 (d, 1H, CH attached to thiazine ring),
5.54 (dd, 1H, CH attached to azetidine ring), 9.59 (d, 1H,
NHAC‚0 of cefotaxime), 3.81 (s, 3H, NOACH3) 6.74 (d,
1H, CH attached to thiazole ring), 7.82 (s, 1H, NHACH2
ANH0), 4.82 (d, 2H, NACH2AN0), 6.31 (s, 1H, CH2ANH0),
6.6–7.2 (m, ring proton of sulphonamide). 13C NMR (DMSO),
d ppm: 23.93 (COACH3), 25.70 (CH2 attached to thiazine),
37.11 (CH2ACOO), 52.01 (CH3ACOO), 52.33 (ANACH2
ANA), 57.77 (CH attached to thiazine), 59.66 (CH attached
to azetidine), 62.99 (NAOACH3), 114.70 (CH attached to
thiazole), 167.50 (COACH3), 168.20 (COOANa), 171.69
(COO), 112.47, 123.88, 145.50, 132.20.
Compound 3d: cefotaxime sodium methyl silver sulphadi-
azine; C27H25AgN9NaO9S3; yield 78%, m.p. 90 C, Anal.
Calcd. C, 38.31; H, 2.98; N, 14.89 Found C, 38.30; H, 2.95;
N, 14.85. IR (KBr) mmax in cm
1 2972 ms CAH Aliphatic,
2946 mas CAH in CAH in CH2, 1770 ms C‚O in beta lactam,
1657 ms C‚O in amide, 1622 ms C‚O in COONa, 1580 ms
C‚N, 1538 NAH bending, 1342 ms S‚O, 1133 CAH in plane
bending vibration of 1:4 disubstituted benzene, 1033 ms NAO.
1H NMR (DMSO) d ppm: 3.77 (s, 3H, CH3ACOO), 2.89 (s,
2H, CH2ACOO), 3.55 and 3.49 (ABq, 2H, CH2 attached to
thiazine ring), 5.10 (d, 1H, CH attached to thiazine ring),
5.50 (dd, 1H, CH attached to azetidine ring), 9.50 (d, 1H,
NHAC‚0 of cefotaxime), 3.82 (s, 3H, NOACH3), 6.78 (d,
1H, CH attached to thiazole ring), 7.88 (s, 1H, NHACH2
ANH), 4.80 (d, 2H, NACH2AN0), 6.34 (s, 1H, CH2ANH0),
6.6–7.2 (m, ring proton of sulphonamide). 13C NMR (DMSO),
d ppm: 25.88 (CH2 attached to thiazine), 37.10 (CH2ACOO),Please cite this article in press as: Joshi, S. et al., Synthesis, spectroscopic characteri
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attached to thiazine), 59.66 (CH attached to azetidine), 62.93
(NAOACH3), 114.76 (CH attached to thiazole), 168.20
(COOANa), 171.71 (COO), 113.44, 128.80, 149.51, 130.25,
156.43.
Compound 3e: cefotaxime sodium methyl Sulphadoxine; C31
H30N9NaO11S3; yield 85%, m.p. 222 C. Anal. Calcd. C,
45.20; H, 3.67; N, 15.30 Found C, 45.12; H, 3.61; N, 15.24.
IR (KBr) mmax in cm
1: 3454 ms NAH, 3381 mas NAH in SO2
NH, 2976 ms CAH in CAH Aliphatic, 2952 mas CAH in CH2,
1772 ms C‚O in beta lactam, 1653 ms C‚O in amide, 1628 ms
C‚O in COONa, 1583 ms C‚N,1536 NAH bending, 1346 ms
S‚O, 1136 CAH in plane bending vibration of 1:4 disubsti-
tuted benzene, 1035 ms NAO.
1H NMR (DMSO) d ppm:
3.73 (s, 3H, CH3ACOO), 2.95 (s, 2H, CH2ACOO), 3.57 and
3.42 (ABq, 2H, CH2 attached to thiazine ring), 5.04 (d, 1H,
CH attached to thiazine ring), 5.59 (dd, 1H, CH attached to
azetidine ring) 9.53 (d, 1H, NHAC‚0 of cefotaxime), 3.84
(s, 3H, NOACH3), 6.70 (d, 1H, CH attached to thiazole ring),
7.82 (s, 1H, NHACH2ANH), 4.79 (d, 2H, NACH2AN0), 6.35
(s, 1H, CH2ANH0), 9.03 (s, 1H, SO2NH), 6.6–7.2 (m, ring pro-
ton of sulphonamide). 13C NMR (DMSO), d ppm: 25.78 (CH2
attached to thiazine), 37.11 (CH2ACOO), 52.06 (CH3ACOO),
52.32 (ANACH2ANA), 57.72 (CH attached to thiazine), 59.64
(CH attached to azetidine), 62.98 (NAOACH3), 114.74 (CH
attached to thiazole), 168.22 (COOANa), 171.60 (COO),
110.63, 113.47, 128.88, 149.50, 157.70, 130.24, 192.97, 199.13.
Compound 3f: cefotaxime sodium methyl sulphadiazine; C27
H26N9NaO9S3; yield 80%, m.p. 160–162 C. Anal. Calcd. C,
43.84; H, 3.54; N, 17.04 Found C, 43.73; H, 3.51; N, 17.07.
IR (KBr) mmax in cm
1: 3460 ms NAH, 3386 mas NAH in SO2
NH, 2979 ms CAH in CAH Aliphatic, 2945 mas CAH in CH2,
1778 ms C‚O in beta lactam,1654 ms C‚O in amide, 1624 ms
C‚O in COONa, 1585 ms C‚N, 1538 NAH bending, 1349
ms S‚O, 1130 CAH in plane bending vibration of 1:4 disubsti-
tuted benzene, 1031 ms NAO.
1H NMR (DMSO) d ppm: 3.77
(s, 3H, CH3ACOO), 2.90 (s, 2H, CH2ACOO), 3.59 and 3.44
(ABq, 2H, CH2 attached to thiazine ring), 5.10 (d, 1H, CH
attached to thiazine ring), 5.60 (dd, 1H, CH attached to azeti-
dine ring), 9.55 (d, 1H, NHAC‚0 of cefotaxime), 3.87 (s, 3H,
NOACH3), 6.79 (d, 1H, CH attached to thiazole ring), 7.81 (s,
1H, NHACH2ANH), 4.75 (d, 2H, NACH2AN0), 6.34 (s, 1H,
CH2ANH0), 9.07 (s, 1H, SO2NH), 6.6–7.2 (m, ring proton of
sulphonamide). 13C NMR (DMSO), d ppm: 25.70 (CH2
attached to thiazine), 37.09 (CH2ACOO), 52.05 (CH3ACOO),
52.33 (ANACH2AN), 57.77 (CH attached to thiazine), 59.65
(CH attached to azetidine), 62.90 (NAOACH3), 114.76 (CH
attached to thiazole), 168.23 (COOANa), 171.69 (COO),
113.47, 128.88, 149.50, 130.24.
Compound 3g: cefotaxime sodium methyl diethanol amine;
C27H27N6NaO9S2; yield 71%, m.p. 225–227 C, Anal. Calcd.
C, 42.42; H, 4.58; N, 14.13 Found C, 42.41; H, 4.51; N,
14.10. IR (KBr) mmax in cm
1: 3465 ms NAH, 3342 ms OAH,
2977 ms CAH in CAH Aliphatic, 2937 mas CAH in CH2, 1765
ms C‚O in beta lactam, 1650 ms C‚O in amide, 1620 ms
C‚O in COONa, 1584 ms C‚N,1531 NAH bending, 1032 ms
NAO. 1H NMR (DMSO) d ppm: 3.73 (s, 3H, CH3ACOO),
2.94 (s, 2H, CH2ACOO), 3.56 and 3.38 (ABq, 2H, CH2
attached to thiazine ring), 5.04 (d, 1H, CH attached to thiazine
ring), 5.57 (dd, 1H, CH attached to azetidine ring) 9.53 (d, 1H,
NHAC‚0 of cefotaxime), 3.56 (t, CH2AOH) 3.84 (s, 3H,
NOACH3), 4.25 (s, CH2AOH), 6.78 (d, 1H, CH attached tozation and Antibacterial screening of some new cefotaxime sodium derivatives.
Figure 1 Powder X-ray diffraction pattern of cefotaxime sodium
methyl silver sulphadiazine (3d).
Effects of some new cefotaxime sodium derivatives 5thiazole ring), 7.84 (s, 1H, NHACH2AN), 3.57 (d, 2H,
NACH2AN0).
13C NMR (DMSO), d ppm: 25.78 (CH2
attached to thiazine), 37.11 (CH2ACOO), 52.06 (CH3ACOO),
52.32 (ANACH2ANA), 56.20 (CH2AOH), 57.72 (CH
attached to thiazine), 59.64 (CH attached to azetidine), 62.98
(NAOACH3), 114.74 (CH attached to thiazole), 168.22
(COOANa), 171.67 (COO), 162.10, 164.96.
Compound 3h: cefotaxime sodium methyl morpholine; C21
H25N6NaO8S2; yield 79%, m.p. 215–218 C, Anal. Calcd. C,
43.75; H, 4.37; N, 14.58 Found C, 43.72; H, 4.33; N, 14.55.
IR (KBr) mmax in cm
1: 3462 ms NAH, 2975 ms CAH Aliphatic,
2933 mas CAH in CH2, 1762 ms C‚O in beta lactam, 1653 ms
C‚O in amide, 1618 ms C‚O in COONa, 1582 ms C‚N,
1528 NAH bending, 1038 ms NAO.
1H NMR (DMSO) d
ppm: 2.40 (t, 2H, NACH2), 3.52 (t, 2H, OACH2), 3.75 (s,
3H, CH3ACOO), 2.94 (s, 2H, CH2ACOO), 3.57 and 3.41
(ABq, 2H, CH2 attached to thiazine ring), 5.02 (d, 1H, CH
attached to thiazine ring), 5.52 (dd, 1H, CH attached to azeti-
dine ring), 9.51 (d, 1H, NHAC‚0 of cefotaxime), 3.84 (s, 3H,
NOACH3) 6.72 (d, 1H, CH attached to thiazole ring), 7.86 (s,
1H, NHACH2AN), 3.57 (d, 2H, NACH2AN0).
13C NMR
(DMSO), d ppm: 25.78 (CH2 attached to thiazine), 37.11 (CH2
ACOO), 52.06 (CH3ACOO), 51.63 (NACH2), 66.81 (OACH2)
52.32 (ANACH2ANA), 57.72 (CH attached to thiazine), 59.64
(CH attached to azetidine), 62.98 (NAOACH), 114.74 (CH
attached to thiazole), 168.22 (COOANa), 171.67 (COO).
Compound 3i cefotaxime sodium methyl Piperazine; C21H26
N7NaO7S2; yield 82%, m.p. 235–236 C, Anal. Calcd. C,
43.82; H, 4.55; N, 17.03 Found C, 43.80; H, 4.52; N, 17.05.
IR (KBr) mmax in cm
1: 3463 NAH, 2972 ms CAH Aliphatic,
2930 mas CAH in CH2, 1762 ms C‚O in beta lactam, 1653 ms
C‚O in amide, 1626 ms C‚O in COONa, 1583 ms C‚N,
1525 NAH bending, 1038 ms NAO.
1H NMR (DMSO) d
ppm: 2.18 (t, 2H, NACH2), 2.64 (t, 2H, NHACH2), 3.72 (s,
3H, CH3ACOO), 2.93 (s, 2H, CH2ACOO), 3.50 and 3.41
(ABq, 2H, CH2 attached to thiazine ring), 5.12 (d, 1H, CH
attached to thiazine ring), 5.58 (dd, 1H, CH attached to azeti-
dine ring), 9.50 (d, 1H, NHAC‚0 of cefotaxime), 3.87 (s, 3H,
NOACH3), 6.73 (d, 1H, CH attached to thiazole ring), 7.85 (s,
1H, NHACH2AN), 3.54 (d, 1H, NACH2AN0).
13C NMR
(DMSO), d ppm: 25.76 (CH2 attached to thiazine), 37.14 (CH2
ACOO), 52.78 (NACH2), 45.90 (NHACH2), 52.02 (CH3
ACOO), 52.37 (ANACH2ANA), 57.79 (CH attached to thia-
zine), 59.62 (CH attached to azetidine), 62.93 (NAOACH3),
114.75 (CH attached to thiazole), 168.26 (COOANa),
171.61(COO).
Compound 3j: cefotaxime sodium methyl diphenyl amine;
C29H27N6NaO7S2; yield 80%, m.p. 220 C. Anal. Calcd. C,
52.88; H, 4.13; N, 12.76. Found C, 52.80; H, 4.10; N, 12.72.
IR (KBr) mmax in cm
1: 3457 ms NAH, 2974 ms CAH Aliphatic,
2943 mas CAH in CH2, 1768 C‚O in beta lactam, 1658 ms
C‚O in amide, 1620 ms C‚O in COONa, 1587 ms C‚N,
1520 NAH bending, 1038 ms NAO.
1H NMR (DMSO) d
ppm: 3.78 (s, 3H, CH3ACOO), 2.98 (s, 2H, CH2ACOO),
3.51 and 3.48 (ABq, 2H, CH2 attached to thiazine ring), 5.20
(d, 1H, CH attached to thiazine ring), 5.53 (dd, 1H, CH
attached to azetidine ring), 9.52 (d, 1H, NHAC‚0 of cefotax-
ime), 3.80 (s, 3H, NOACH3) 6.79 (d, 1H, CH attached to thi-
azole ring), 7.86 (s, 1H, NHACH2AN), 3.57 (d, 2H,
NACH2AN0).
13C NMR (DMSO), d ppm: 25.68 (CH2
attached to thiazine), 37.17 (CH2ACOO), 52.03 (CH3ACOO),
52.42 (ANACH2ANA), 57.78 (CH attached to thiazine), 59.66Please cite this article in press as: Joshi, S. et al., Synthesis, spectroscopic characteri
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attached to thiazole), 126.45, 128.96 and 146.08 (CH attached
to phenyl), (168.24 (COOANa), 171.59 (COO), 143.06, 164.10,
163.32, 162.12.
2.2.2. Powder X-ray diffraction studies
Powder X-ray diffraction patterns of three synthesized com-
pounds namely cefotaxime sodium methyl silver sulphadiazine
(3d), cefotaxime methyl morpholine (3h) and cefotaxime
methyl Piperazine (3i) (Figs. 1–3 respectively) were reported.
Average particle size of the synthesized compounds was
determined with the help of the Scherrer formula, in which
particle size D is deﬁned as:
0:9k=B cos h;
where 0.9 = constant, k=wavelength, B= angular width
and h= diffraction angle. Average particle size of the
compounds determined was 53.33, 17.26 and 22.99 nm
respectively.
2.2.3. Scanning Electron Microscopy (SEM) studies
Scanning Electron Microscopy Studies of two of the synthe-
sized compound namely cefotaxime sodium methyl silver
sulphadiazine (3d) and cefotaxime methyl Piperazine (3i) were
carried out at magniﬁcation of ·1000–10 lm and ·600–2 lm.
SEM uses a focused beam of high energy electrons to generate
a variety of signals from the surface of signals revealing infor-
mation about the sample, including external morphology,
topography, chemical composition crystalline structure, and
orientation of materials making up the sample. SEM was
recorded different images of each compound at different mag-
niﬁcations, as described above.
Compound cefotaxime sodium methyl silver sulphadiazine
(3d) (Figs. 4 and 5) has a different topography and morphol-
ogy at two different magniﬁcations. In images, the particles
exhibit approximately round Shape with different sizes.
Cefotaxime sodium methyl Piperazine (3i) is shown in
Figs. 6 and 7 with different magniﬁcations. This compound
has also round particles in different sizes. SEM studies showzation and Antibacterial screening of some new cefotaxime sodium derivatives.
Figure 2 Powder X-ray diffraction pattern of cefotaxime sodium
methyl morpholine (3h).
Figure 3 Powder X-ray diffraction pattern of cefotaxime sodium
methyl Piperazine (3i).
Figure 4 SEM image of cefotaxime sodium methyl silver
sulphadiazine (magniﬁcation of ·1000–10 lm).
Figure 5 SEM image of cefotaxime sodium methyl silver
sulphadiazine (magniﬁcation of ·600–2 lm).
Figure 6 SEM image cefotaxime sodium methyl Piperazine
(magniﬁcation of ·1000–10 lm).
Figure 7 SEM image cefotaxime sodium methyl Piperazine
(magniﬁcation of ·600–2 lm).
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Table 1 Antibacterial screening of synthesized cefotaxime sodium derivatives and sulphonamides against E. Coli and S. aureus (zone
of inhibition in mm).
Comp. No. E. coli concentration in lg/ml S. aureus concentration in lg/ml
80 160 320 Avg. 80 160 320 Avg.
3a 5.6 7.6 8.8 7.3 16.4 20.0 25.3 20.5
3b – – – – 9.3 10.6 13.1 11.0
3c – – – – 15.3 18.0 21.0 18.1
3d 11.6 20.3 23.3 18.4 9.3 11.0 14.3 11.5
3e 13.3 14.0 17.6 14.9 7.3 10.6 12.3 10.0
3f 12.3 17.6 21.6 17.1 16.4 19.2 24.3 19.96
3g – – 9.0 3.0 – – 8.3 2.7
3h – – 14.6 4.8 – 9.0 11.6 6.8
3i 6.8 8.0 10.3 8.3 – 11.0 16.6 9.2
3j – – 15.3 5.1 – – 11.6 3.8
2a 12.0 16.6 20.0 16.2 15.6 18.2 21.3 18.3
2b 14.5 17.0 19.0 16.8 15.3 19.0 20.0 18.1
2c 14.0 16.3 20.0 16.7 10.6 16.0 19.3 15.3
2d 9.5 11.8 17.6 12.9 9.0 11.0 14.6 11.5
2e 9.6 10.3 16.0 11.7 7.3 8.3 11.0 8.8
*Avg: average value of antibacterial activity (for 80, 160 and 320 lg).
Effects of some new cefotaxime sodium derivatives 7microstructure of the compounds, which mainly include sur-
face morphology.
2.3. Antimicrobial activity and LD50 test
The newly synthesized cefotaxime sodium derivatives (3a–3j)
were screened for their antibacterial activity against patho-
genic strains of Escherichia coli and Staphylococcus aureus at
varying concentrations – 80 lg/ml, 160 lg/ml and 320 lg/ml
using corresponding sulphonamide as their standards by cup
plate method. Nutrient agar media were prepared for bacterial
growth. The media were autoclaved at 15 lbs pressure
(121.6.C) for 30 min. The culture of bacterium was mixed with
autoclaved media and poured in plates and bored. The solu-
tion of cefotaxime sodium derivatives was poured in these cups
in triplicate and incubated at 37 C for 24 h. Antibacterial
activity was ascertained by the zone of inhibition measured
in mm as shown in Table 1. The similar procedure was fol-
lowed for the parent sulphonamide.
The toxicity of synthesized cefotaxime sodium derivatives
was ascertained by LD50 test. The test was performed on white
mice weighing 25 g. Doses were given orally as well as intraper-
itoneally and mice were kept under observation for 72 h for
each trial. The cefotaxime sodium derivatives showed no
adverse toxic effect even of an oral dose of 1400 mg/kg of
the body weight of mice. However, when dose was adminis-
tered intraperitoneally they proved to be lethal at the dose level
of 750 mg/kg of the body weight of mice.3. Results and discussion
The cefotaxime sodium derivatives synthesized by aminome-
thylation reaction were obtained in good yield (P85%). They
were analysed for elemental analysis and results were found to
be in full agreement with the calculated values. The anticipated
structure was in agreement with the spectral data of IR and
NMR. The purity of synthesized compounds was assured with
aid of chromatographic technique. The stationary phase was
silica gel-G. It was of chromatographic grade. The solventsPlease cite this article in press as: Joshi, S. et al., Synthesis, spectroscopic characteri
Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.031used for mobile phase were methanol and chloroform. They
were distilled before using. The spectral studies have shown
characteristic band of methylene group incorporated between
cefotaxime sodium and the amine component due to aminome-
thylation. This shows the presence of amino methyl linkage in
the synthesized cefotaxime sodium derivatives. The NMR also
conﬁrms amino methyl linkage (ACH2) between amine and
active hydrogen. Some of the synthesized compounds were
nanosize. The use of nanoparticle in medicine offers some
exciting possibilities. Some techniques are only imagined, while
others are at various stage of testing, or actually being used
today. The cefotaxime sodium derivatives were screened for
their biological signiﬁcance. They were evaluated for antibac-
terial activity against pathogenic strains of E. Coli, S. aureus
at varying concentrations – 80, 160 and 320 lg/ml. These
pathogens were subcultured on speciﬁc media. The cefotaxime
sodium derivatives and the standard compound (sulphona-
mide and secondary amines) were dissolved in DMF. The
reported activities were mean of zone of inhibition in millime-
tre (in triplicate). All the reported compounds exhibit remark-
able in vitro activity against these pathogens. Their activity
was also compared with their parent sulphonamide.
Table 1 reﬂects that most of the compounds had shown
remarkable activity only at 320 lg/ml. Antibacterial screening
of cefotaxime sodium derivatives against E. coli shows interest-
ing results. 3d was superior to other followed by 3f and 3e in
inhibiting the growth of this pathogen. Comparison with
parent sulphonamide shows that compound 3d and 3e were
superior to the corresponding sulphonamide.
Cefotaxime sodium derivatives had shown signiﬁcant
activity against S. aureus. The compounds 3a, 3f, and 3c were
signiﬁcantly superior to other compounds in exhibiting anti-
bacterial activity against S. aureus. Comparative study with
sulphonamides indicates that compounds 3a, 3c and 3e are
superior to the corresponding sulphonamides. Moreover,
concentration 320 lg/ml was superior for inhibiting the growth
of the bacterium.
Comparison of cefotaxime sodium derivatives with sulph-
onamides shows that, some cefotaxime sodium derivatives
are having more antibacterial activity, but former is less toxiczation and Antibacterial screening of some new cefotaxime sodium derivatives.
8 S. Joshi et al.than latter as revealed by LD50 test on white mice of weight
25 gm. The newly synthesized compounds seems to be really
promising compounds for their antibacterial activity. In the
light of those ﬁnding we will undertake further synthetic stud-
ies on the new compounds in the future.
4. Conclusion
This work shows that cefotaxime sodium derivatives are a
potential source of compounds for inhibition of bacteria and
could be used as efﬁcient drugs with minimum side effects.
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